Reductil is an FDA-approved drug treatment for obesity. It is recommended for weight loss in combination with physical activity, behavior alterations and a healthy diet. It may also be used not only by overweight patients, but also by patients who suffer from comorbidities associated to overweight, such as diabetes, heart disease or high blood pressure in order to reduce the burden of the diseases.
Available in both tablets and capsules, the medication was developed by Gate Pharmaceuticals, which is now part of Abbott Pharmaceuticals. Sibutramine was approved by the FDA in the 1959 and it is an appetite suppressant, belonging to the sympathomimetic amines class of drugs. Physicians usually recommend the use of one pill or capsule per day, an hour before breakfast — a dosage that may be adjusted by the physician up to two times a day. Reductil is commercialized as a short-term treatment, which is supposed to take only a few weeks.
History of Reductil
Until 1996, Sibutramine or Reductil was one of the two only drugs approved by the FDA for weight loss, the other one being Sibutril (France). There are currently other drug therapies available in the UK. for obese patients, but Reductil remains a reliable method to be used in the short-term. The FDA approved the use of 10 miligrams of sibutramine hydrochloride, which are commercialized by Abbott since the 1990s in capsules or tablets.
Before the approval, Reductil was submitted to a rigorous scientific process, during which it was reviewed by physicians, statisticians, chemists, pharmacologists, and other scientists. Since the approval of the generic form of sibutramine, few studies were conducted to analyze the drug. Among the research made, Sibutramine stands out the one made to evaluate the benefits of the drug in combination with Phentermine.
How Reductil Works
Being a sympathomimetic amine, Reductil operates by its active metabolites inhibiting the reuptake of noradrenalin serotonin and to a lesser extent dopamine. This action enhances "satiety" or the feeling of being full, and this reduces food intake. In addition to appetite suppression, other actions related to the central nervous system and metabolic system may also be involved. In addition Reductil also has a "thermogenic" effect by which it increases the level of calories burnt while at rest, during a weight loss programme.
Other Details About Reductil
Reductil is not recommended for patients who have a history of heart disease, pulmonary hypertension, severe or uncontrolled high blood pressure, overactive thyroid, glaucome, drug or alcohol abuse or by pregant women. Reductil is also not recommended for people who took an MAO inhibitor in the past 14 days or in combination with other diet medication, including fendluramine and dexfenfluramine, which can result in severe side effects.
Most important cause effects of Reductil include dizziness, dry mouth, difficulty sleeping, irritability, nausea, vomiting, diarrhea, or constipation. In addition, patients may suffer withdrawal symptoms like depression or severe tiredness, and abnormal drug-seeking behavior. However, the cases of addiction are rare. Since it is a short-term treatment, Reductil may stop working, following a few weeks of treatment, a problem that should be discussed with a physician in order to adapt the treatment to the patient’s needs.